Compare WAFU & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAFU | BGLC |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 10.1M |
| IPO Year | 2019 | N/A |
| Metric | WAFU | BGLC |
|---|---|---|
| Price | $1.73 | $4.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 205.8K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,186,645.00 | ★ $9,465,006.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.21 |
| 52 Week Low | $1.22 | $2.01 |
| 52 Week High | $7.49 | $15.60 |
| Indicator | WAFU | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 39.04 |
| Support Level | $1.51 | $4.01 |
| Resistance Level | $1.60 | $4.29 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 32.81 | 32.43 |
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.